TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8915574
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of truncated trkB receptors found in senile plaques in Alzheimer's disease brains.
Study: 8915574
Drug: Full-length trkB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-length trkB receptor expression in glial-like cells in the hippocampus of Alzheimer's disease brains.
Study: 8915574
Drug: Elevated trk
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated trk receptor mRNA levels in Alzheimer's disease brains as indicated by in-situ hybridisation studies.
Study: 1910794
Drug: Alfentanil 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 0.01 mg/kg
Study: 27852903
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg/day)
Study: 27852903
Drug: Risedronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (35 mg/week)
Study: 21519752
Drug: 5·10(8) cfu/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5·10(8) cfu/day of L. plantarum CECT7315/7316 (low probiotic dose) (n = 13)
Study: 21519752
Drug: 5·10(9) cfu/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5·10(9) cfu/day of the probiotic mixture (high probiotic dose) (n = 19)
Study: 12767365
Drug: Alternating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating therapy with mitomycin C (MMC) and bacillus Calmette‐Guerin (BCG)
Study: 27603424
Drug: BCG monotherapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG monotherapy
Study: 3910908
Drug: Native thrombolytic
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native thrombolytic drugs (streptokinase or urokinase) administered to 30 patients
Study: 28272175
Drug: Nebulized fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized fluticasone 1,000 µg
Study: 23690356
Drug: Tetracaine hydrochloride-oxymetazoline
Normalized name: oxymetazoline / tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine hydrochloride-oxymetazoline hydrochloride nasal spray bilaterally with sham injection
Study: 23690356
Drug: Intra-oral lidocaine-epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-oral lidocaine-epinephrine injection with buffered saline nasal spray bilaterally
Study: 20949350
Drug: Risperidone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (6 mg/day) plus sildenafil (75 mg/day)
Study: 14649206
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Steroid, cyclophosphamide, losartan, and dipyridamole)
Study: 3193409
Drug: Parenteral combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral combination therapy (cefoxitin plus doxycycline or ceftizoxime plus doxycycline)
Study: 3193409
Drug: Monotherapy (ceftizoxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (ceftizoxime alone)
Study: 25971261
Drug: Low-dose ribavirin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ribavirin
Study: 15014183
Drug: BIBN 4096
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBN 4096 BS 2.5 mg
Study: 15014183
Drug: BIBN 4096
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBN 4096 BS (all doses)
Study: 9043563
Drug: Intervention 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention 1: Placement of a brightly colored label in the medication drawer and on the cover of the nursing medication card flip-chart.
Study: 8172701
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment evaluation method
Study: 31697729
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg.kg-1 body mass)
Study: 19906075
Drug: Alitretinoin 30
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 30 mg once daily for 12-24 weeks
Study: 18678156
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (no EA)
Study: 12580681
Drug: Home intervention
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home intervention with weekly visits from 0 to 6 months and biweekly visits from 6 to 18 months
Study: 8768860
Drug: Combination recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination recombinant human GH (rhGH; 0.34 mg, sc, twice daily) and rhIGF‐I (5.0 mg, sc, twice daily)
Study: 29857783
Drug: Fluticasone propionate/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/formoterol fumarate (Flutiform®; 100/10 µg b.i.d.)
Study: 27163503
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg Opicapone (OPC)
Study: 27163503
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Opicapone (OPC)
Study: 20377423
Drug: RBV 2000
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV 2000 mg/day plus EPO 30,000 IU/week
Study: 20377423
Drug: Weight-based RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based RBV (1000-1200 mg/day)
Study: 2265733
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection therapy (CT)
Study: 30320641
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg) in group D
Study: 30320641
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg) in group L
Study: 30320641
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg) with Dexamethasone (8 mg) in group DL
Study: 27159624
Drug: Group DM
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group DM (0.1 mg/kg dezocine + 0.05 mg/kg midazolam)
Study: 27159624
Drug: Groups D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups D and DM (0.1 mg/kg dezocine)
Study: 27159624
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (0.1 mg/kg dezocine)
Study: 27159624
Drug: Groups M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups M and DM (0.05 mg/kg midazolam)
Study: 12600867
Drug: Iron-only supplementation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-only supplementation, 6 days/week, containing 60 mg Fe
Study: 10978257
Drug: Simvastatin therapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin therapy (20 mg per day for 4 months)
Study: 8984133
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg once a day
Study: 30608444
Drug: OSTAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSTAP block with 40 mL of 0.375% bupivacaine
Study: 30608444
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group with 40 mL of 0.9% saline
Study: 26643786
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl aminolevulinate (MAL) and daylight
Study: 21730016
Drug: Tiagabine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (4 mg, 8 mg, 12 mg)
Study: 15850603
Drug: Estrogen (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (conjugated equine estrogen [CEE] 0.625 mg)
Study: 10096309
Drug: Alcohol (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (blood alcohol concentration mean = .08 mg%)
Study: 7635769
Drug: Treatment duration
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment duration < 55 days
Study: 7635769
Drug: Treatment duration
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment duration >= 55 days
Study: 7635769
Drug: Stage IB/IIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage IB/IIA treatment duration < 55 days
Study: 7635769
Drug: Stage IB/IIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage IB/IIA treatment duration >= 55 days
Study: 7635769
Drug: Stage III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage III treatment duration < 55 days
Study: 7635769
Drug: Stage IIB
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage IIB treatment duration >= 55 days
Study: 2144391
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (20 micrograms)
Study: 2144391
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination (2 micrograms)
Study: 625669
Drug: Phenoxybenzamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxybenzamine treatment after urinary retention
Study: 28019652
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in WHO risk drinking levels during treatment
Study: 25212749
Drug: Sertraline (200mg/day)
Normalized name: sertraline 200 MG
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (200mg/day) with DRD4 <7 repeats
Study: 17265490
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate 1,500 mg once daily (n = 106)
Study: 15354322
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) 6 g/day
Study: 17214993
Drug: AGI‐1067 280
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGI‐1067 280 mg qd for 12 months after PCI
Study: 15470797
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg naloxone administered intravenously
Study: 3085789
Drug: Sodium etidronate
Normalized name: Sodium etidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium etidronate 20 mg/kg/day for two and four weeks
Study: 3085789
Drug: Sodium etidronate
Normalized name: Sodium etidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium etidronate 20 mg/kg/day for four weeks
Study: 3085789
Drug: Sodium etidronate
Normalized name: Sodium etidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium etidronate 20 mg/kg/day for two weeks
Study: 11578893
Drug: Air-O(2) mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-O(2) mixture with FGF 0.5 L/min (4/1 ratio)
Study: 11578893
Drug: Air-O(2) mixtures
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-O(2) mixtures with FGF < or = 2 L/min
Study: 26516803
Drug: Ultrasound-guided single-injection
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided single-injection infraclavicular block
Study: 26516803
Drug: Ultrasound-guided double-injection
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided double-injection axillary block
Study: 24619917
Drug: Pradigastat co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradigastat co-administered with digoxin
Study: 24619917
Drug: Pradigastat co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradigastat co-administered with warfarin
Study: 18068064
Drug: Fenoldopam infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam infusion (0.1 microg/kg/min)
Study: 15654790
Drug: Alosetron (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron (0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg)
Study: 25391382
Drug: Antidementia drugs
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidementia drugs (memantine, donepezil, rivastigmine, galantamine)
Study: 25391382
Drug: Antidementia drugs
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidementia drugs
Study: 11330505
Drug: Intact insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intact insulin
Study: 31919502
Drug: Metabolic pathway
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolic pathway glycine, serine, and threonine metabolism
Study: 25416584
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of standard rehabilitation interventions and scapulothoracic joint control training exercises
Study: 16360199
Drug: Low-dose Z-100
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Z-100 (0.2 microg)
Study: 16360199
Drug: High-dose Z-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Z-100 (40 microg)
Study: 10378565
Drug: Kinetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetic therapy (KT) combined with mechanical percussion (P) using a KT system (Triadyne Kinetic Therapy System; KCI; San Antonio, TX)
Study: 8777824
Drug: Hyperglycaemia (8.5‐10.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (8.5‐10.5 mmol/l)
Study: 1380475
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion during ERCP
Study: 31054101
Drug: Chemotherapy (CHT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CHT) - temozolomide 200 mg/m2/day for 5 days every 28 days
Study: 25826322
Drug: RGN‐259 (0.1%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RGN‐259 (0.1%) eye drops, 6 times daily for 28 days
Study: 21422759
Drug: Human tissue
Normalized name: Recombinant human tissue kallikrein-1
DrugBank: Recombinant human kallikrein-1 (DB19232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human tissue kallikrein with conventional treatment over 12-14 days
Study: 8562742
Drug: Zaldaride maleate
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaldaride maleate (20 mg four times per day)
Study: 2642629
Drug: Oral milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral milrinone
Study: 30238650
Drug: Self-management intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management intervention using teach-back, including individual teaching session, heart failure booklet, weighing scales, diary for daily weight, follow-up phone call 2 weeks after discharge.
Study: 25446376
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus sorafenib (1000 mg/m2 once weekly for 7 weeks + 1 week rest, then once every 3 weeks + 1 week rest)
Study: 20237316
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg subcutaneously and 75 mg of aspirin orally once daily along with intense pregnancy surveillance
Study: 31373112
Drug: Topical Citrullus
Normalized name: Citrullus colocynthis fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Citrullus colocynthis oil
Study: 27502326
Drug: Fimasartan 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 60 mg
Study: 22306735
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with STAMP-V (carboplatin, thiotepa, and cyclophosphamide), ACT (doxorubicin, paclitaxel, and cyclophosphamide), or tandem melphalan and STAMP-V
Study: 17763111
Drug: Active bupropion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active bupropion and active 4‐mg gum (AA)
Study: 11598360
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hormonal pre‐medication)
Study: 8682138
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atenolol and nifedipine
Study: 25545026
Drug: Oral fingolimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fingolimod 0.5mg once daily
Study: 25545026
Drug: Oral fingolimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fingolimod 1.25mg once daily
Study: 25545026
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon β‐1a (IFNβ‐1a IM) 30 μg/mL once weekly
Study: 19248104
Drug: 0.9% MQX-503
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% MQX-503 gel
Study: 17087689
Drug: Occupational/Physical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational/Physical Therapy (OT/PT) intervention delivered via teletechnology or in-home visits
Study: 8378244
Drug: Remoxipride oral
Normalized name: remoxipride Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride oral suspension (100 mg dose)
Study: 24664172
Drug: Valacyclovir 1
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1 g orally each day for 2 months
Study: 15386328
Drug: Invasive breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive breast cancer patients with oestrogen receptor-negative tumours
Study: 2493710
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg/kg, vecuronium bromide 0.1 mg/kg intravenously, and 3 vol.% isoflurane in oxygen for induction; nitrous oxide 66% in oxygen and 0.9 vol.% isoflurane for maintenance
Study: 30394344
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg of rectal misoprostol before cesarean section
Study: 30394344
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg of rectal misoprostol after cesarean section
Study: 19922671
Drug: Insulin Resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Resistance (IR) assessed by HOMA-IR
Study: 9146851
Drug: Transdermal delivery
Normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal delivery of acetylcholine via iontophoresis (150 microA for 40 s) at various sites in the forearm and hand
Study: 2834115
Drug: Heparin pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin pretreatment (5000 IU IV before exercise)
Study: 27664548
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (CBGT) with 12 sessions, two involving family members
Study: 23374199
Drug: Strain-counterstrain treatment
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strain-counterstrain treatment
Study: 9186253
Drug: Vigabatrin (3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (3,000 mg daily for 4 weeks)
Study: 27084855
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (Control group)
Study: 29685693
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg daily for 15 days
Study: 22453707
Drug: Link Samahan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Link Samahan® (one sachet daily in hot water)
Study: 18426595
Drug: IFN beta‐1a,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN beta‐1a, 44 mcg subcutaneously (sc) three times weekly (tiw)
Study: 18426595
Drug: IFN beta‐1a,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN beta‐1a, 30 mcg intramuscularly (im) once weekly (qw)
Study: 11037895
Drug: Diacerein 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein 100 mg/day (50 mg twice daily)
Study: 11037895
Drug: Diacerein 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein 150 mg/day
Study: 8803379
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (IVL) 2 mg/kg
Study: 8803379
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (IVL) 5 mg/kg
Study: 8887580
Drug: Oral mexiletine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mexiletine
Study: 1730902
Drug: Heat-inactivated anti-HIV
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated anti-HIV antibody-rich plasma (7 transfusions every 2 weeks)
Study: 1730902
Drug: Heat-inactivated anti-HIV
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated anti-HIV antibody-rich plasma
Study: 18495737
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of albendazole daily for 8 days
Study: 9292380
Drug: Home-based multisystemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based multisystemic therapy
Study: 1750591
Drug: Protamine titration
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine titration using the Hemochron system
Study: 1750591
Drug: Empirical dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical dose protocol
Study: 29199654
Drug: Radiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and concurrent cisplatin infusion (Group B)
Study: 18089874
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 intravenously on day 1 without raltitrexed
Study: 15336467
Drug: Controlled-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release oxybutynin (15 mg/d, adjusted in 5 mg/d increments)
Study: 11876710
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg/day for 2 weeks
Study: 11876710
Drug: Pantoprazole, 40
Normalized name: Pantoprazole, 40 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole, 40 mg/day for 2 weeks
Study: 9632571
Drug: Conjugates and
Normalized name: conjugated estrogens and bazedoxifene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugates and cellular vaccine
Study: 3311661
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg cisapride